KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Short-term Investments (2016 - 2025)

Pacira BioSciences has reported Short-term Investments over the past 15 years, most recently at $79.9 million for Q4 2025.

  • Quarterly results put Short-term Investments at $79.9 million for Q4 2025, down 61.57% from a year ago — trailing twelve months through Dec 2025 was $79.9 million (down 61.57% YoY), and the annual figure for FY2025 was $79.9 million, down 61.57%.
  • Short-term Investments for Q4 2025 was $79.9 million at Pacira BioSciences, down from $98.7 million in the prior quarter.
  • Over the last five years, Short-term Investments for PCRX hit a ceiling of $559.8 million in Q3 2021 and a floor of $70.8 million in Q4 2021.
  • Median Short-term Investments over the past 5 years was $170.8 million (2022), compared with a mean of $215.0 million.
  • Biggest five-year swings in Short-term Investments: tumbled 83.2% in 2021 and later skyrocketed 160.5% in 2022.
  • Pacira BioSciences' Short-term Investments stood at $70.8 million in 2021, then skyrocketed by 160.5% to $184.5 million in 2022, then tumbled by 32.1% to $125.3 million in 2023, then skyrocketed by 65.9% to $207.8 million in 2024, then tumbled by 61.57% to $79.9 million in 2025.
  • The last three reported values for Short-term Investments were $79.9 million (Q4 2025), $98.7 million (Q3 2025), and $145.4 million (Q2 2025) per Business Quant data.